CAMBRIDGE | Enterprise Ventures

30 Years

University Venturing
1995-2025

2 Foreword

Christine Martin
DPhil

Head of Ventures,
Cambridge Enterprise

Cambridge Enterprise Ventures is proud to be the direct investing arm of the University of Cambridge, supporting startups and spinouts with a strong founder or technology connection to the University. Since our establishment in 1995, over 210 companies have been launched with the help and support of Ventures. Our model allows for the full recycling of realisation income, enabling today's successful businesses to support the startups of tomorrow. Over the last 30 years we have recycled £44.5 million back into the funds, with each set of returns allowing us to do more to support University connected businesses.

Here in Cambridge, our investment funds leverage third-party capital to help establish exceptional spinouts, with the portfolio attracting over £3.5 billion of investment since 1995. In turn, each successful company becomes a hub for innovation within the ecosystem, driving employment, social impact and technology development. Companies such as Riverlane, Xampla and T-Therapeutics are now pushing the innovation envelope on a global stage and are making a significant, impactful contribution to society and the Cambridge story.

All this is possible because of the vision shown by the University Treasurer, Joanna Womack, back in 1995. Thank you.

University venture investment in numbers

£74.8m
asset value at 31/07/24

£55m
total amount invested at 31/07/25

1:64
capital leverage ratio

£3.5bn
amount raised by portfolio companies to 31/07/2025

212
number of companies supported

£44.5m
realisations

66
full and partial exits

£14.7m
total amount invested into exited companies

3.03
multiple on realised investments

1995
University Venture Fund established by Finance Committee

1996
Sale of CADCentre shares provides first returns to the fund

1999
Venture Fund invests in Entropic

2000
University Challenge Fund, established with £4 million – Independent Investment Committee and team set up

2001
First University investment into BlueGnome and Solexa

2002
Astex Seed investment completed

2003
First investment into CamFridge

2004
Cambridge Display Technology raises $30 million in a NASDAQ IPO

2005
Pre-seed investment made into Enecsys

2006
CADCentre provides 4x return on our investment

2007
Next generation genome sequencing startup Solexa acquired by Illumina for $650 million

2008
University Discovery Fund established with philanthropic raise

2010
Pathfinder to Sphere Bio Ltd starts the Cyto-Mine® journey

2011
Assets under management total £7.7 million

2012
BlueGnome exit to Illumina

2013
Astex Pharmaceuticals acquired by Otsuka Group (est. $900 million)

2014
Horizon Discovery IPO raises £68 million

2015
VocalIQ, who introduced the worlds first self-dialogue API, is bought by Apple

2016
CCMOSS acquired by AMS for a 4x return on our investment

2017
Echion starts with a Pathfinder

2018
Lumora acquired by ERBA Diagnostics Mannheim for a 6x return on our investment.

Quethera acquired by Astellas

2019
Riverlane and Colorifix seed rounds complete

2020
UCAM invests further £30 million into the Venture Fund with at least £7 million to be committed to sustainability

2021
Pharmaceutical giant Centessa Pharmaceutics raises $330 million - one of the largest public offerings of 2021 by a biotech

2022
Gyroscope acquired with $800 million upfront by Novartis

2023
Scalable quantum-computer network pioneer Nu Quantum raises £7 million follow-on funding

2024
Assets under management total £75 million

2025
CellCentric secures $120 million towards Phase III studies

Nyobolt raises $30 million

8

History

The University Venture Fund was established in 1995 by the University Finance Committee to manage direct investment activity on behalf of the University. A range of shareholdings were transferred by the University into the new fund, together with a cash allocation from the University's balance sheet.

The first investment was made into Cambridge Display Technology (CDT) in 1995. CDT later floated on NASDAQ, providing returns the the Venture Fund. Other early realisation income came from the sale of CADCentre shares. This income helped to increase the liquidity of the fund in the early years, initiating the cycle of investment and returns that remains in place today.

In 2000, the University, in collaboration with the Babraham Institute, successfully applied for University Challenge funding to establish a £4 million seed fund. This significantly boosted the internal capital that was available to invest.

As part of the University's 800th anniversary celebrations in 2008, Cambridge Enterprise established the Discovery Fund, a philanthropic fund that raised £1.8 million to invest in technologies generated in research laboratories and to support the University's commercialisation activity. Together, these funds provided £8 million in initial seed capital for University-connected businesses.

In 2020, the University Bond purchased a stake in the assets of the Venture Fund, providing additional investment capital to support the growing startup ecosystem.

All exited investments made to date

Investment	Returns Category
ams Sensors UK Limited	Top
Astex Therapeutics Limited	Top
BlueGnome Limited	Top
CADCentre Limited	Top
Cambridge CMOS Limited	Top
Cambridge Display Technology Limited	Top
Centessa Pharmaceuticals Plc	Top
Cytora Limited (partial)	Top
Enecsys UK Limited	Top
Entropic Limited	Top
FLUSSO Limited	Top
Galapagos NV	Top
Genapta	Top
Gyroscope Therapeutics Holdings Plc	Top
Horizon Discovery Limited	Top
Illumina Cambridge Limited	Top
Lumora Limited	Top
Phoremost Limited	Top
Psynova Neurotech Limited	Top
Quethera Limited	Top
Smart Holograms Limited	Top
Versed AI Ltd	Top
VocalIQ Limited	Top
XO1 Limited	Top
16 companies	Mid
25 companies	Nil

The top returning companies have provided sufficient capital to continue to support the funds, alongside the recent injection of capital from the University Bond to enable further growth in activities.

The mid-returning companies provided a level of returns for the funds, while the nil returners encountered technical or commercial failure, which is to be expected in any early-stage, high-risk investment portfolio.

Established
2013

Acquired by
Astellas

Life Sciences

Total raised
£625k

>11x
Realisation
multiple

Founders
Professor Keith Martin, Peter Widdowson

Quethera

Quethera Limited was a gene therapy company focused on developing novel treatments for ocular disorders, such as glaucoma, which can cause blindness and severly affect patients' quality of life. The company raised £625k from a syndicate, including UKI2S, before it was acquired by Astellas Pharma Inc. Under the terms of the purchase agreement, Astellas may pay up to £85 million in aggregate consideration (upfront and contingent payments), so it remains possible that further realisations will be received.

Established
2008

Acquired by
By ams AG

Physical
Sciences

Total raised
£7.1m

>4x
Realisation
multiple

Founder
Professor Florian Udrea

CCMOS

Cambridge CMOS Sensors Limited (CCMOSS), acquired by ams AG in 2016, specialised in MEMS micro-hotplates for gas sensors used in automotive, industrial, medical and consumer markets. Their deep expertise in this area complemented ams' technology leadership in MOX gas sensing materials to detect gases like CO, NOx, and VOCs. CCMOSS manufactured these MEMS structures on CMOS wafers, creating highly cost-efficient, complete monolithically integrated CMOS sensor ICs. These solutions offered advantages such as low power consumption, small footprint and the ability to integrate additional sensor modalities like relative humidity, temperature and pressure.

Established
2008

Acquired by
Apple, Inc

Physical
Sciences

Total raised
£1.1m

Founders
Professor Steve Young, Blaise Thomson

VocalIQ

VocalIQ offered transformative new software that used a fresh approach to solve the limitations of earlier previous voice recognition systems. The software allowed dialogue between human and machine, providing a seamless interface between people and their mobile devices, televisions and cars and was ultimately incorporated into the Apple Siri system.

Established
2013

Acquired by
Janssen
Pharmaceuticals

Life Sciences

Total raised
£7.1m

>13x
Realisation
multiple

Founders
Professor Jim Huntington,
Dr Trevor Baglin

XO1

XO1 Limited was a spinout from the University of Cambridge and Cambridge University Hospitals, established to develop a new anticoagulant drug, Ichorcumab, which had the potential to save millions of lives by preventing heart attacks and strokes, without causing bleeding.

The company raised £7.1 million from a syndicate including Index Ventures before being acquired by Janssen Pharmaceuticals, Inc. Following a Phase 2 clinical study, published in the journal Thrombosis in 2019 the programme is no longer being pursued.

Established
1998

Acquired by
Illumina, Inc

Life Sciences

Total raised
£114m

Founders
Professor Sir Shankar Balasubramanian,
Professor Sir David Klenerman

Solexa

The Solexa method for colour-coded, solid-phase DNA sequencing by synthesis that could be made massively parallel has enabled researchers worldwide to investigate the genetics of life at a scale and depth never before achievable. The genomes of many organisms have been sequenced from humans to wheat, providing deep insights. These have helped us to, for example, understand human illness better and to reveal secrets of evolutionary development of organisms. Solexa was acquired by Illumina for $650 million in 2006.

Established
1992

Acquired by
Sumitomo, IPO
2004

Physical
Sciences

Total raised
£85m

>2x
Realisation
multiple

Founder
Professor Richard Friend

Cambridge Display Technology

Cambridge Display Technology (CDT) was established to commercialise the polymer organic light-emitting diode (P-OLED) technology that was developed in Richard Friend's research group at the Cavendish Laboratory. An initial manufacturing-based strategy was switched to a licensing model in the mid-1990s and CDT became the first University of Cambridge spinout to be listed on NASDAQ in 2004. Later, the company was acquired by Sumitomo in 2007 for $285 million.



Established
1967

Acquired by
Schneider
Electric, IPO
1996

Physical
Sciences

>4x
Realisation
multiple

Founders
Dr Bob Bishop, Professor John Ward

CADCentre

CADCentre was founded in 1967 as a government-funded research institute, created by the UK Ministry of Technology, with a mission to develop computer-aided design techniques and promote their uptake by industry. The University held shares in the project, which was established as a subsidiary business. These shares and some loans were transferred to the Venture Fund on its establishment in 1995, and its listing on the London Stock Exchange in 1996 helped generate early liquidity for the fund. CADCentre still exists today as AVEVA and was acquired by Schneider Electric in 2023.

Established
2016

Acquired by
Novartis

Life Sciences

Total raised
£214m

>3x
Realisation
multiple

Founder
Professor Sir Peter Lachmann

Gyroscope Therapeutics

Gyroscope developed the world's first treatment for geographic atrophy, an advanced form of dry age-related macular degeneration that leads to blindness. Gyroscope grew into a global leader in ocular gene therapies, combining discovery, research, drug development and proprietary surgical and manufacturing platforms. Its team of nearly 200 employees were executing on its Phase II clinical trials for the treatment of geographic atrophy secondary to age-related macular degeneration, having generated positive clinical data in its Phase I/II FOCUS trial when it was acquired by Novartis for up to $1.5 billion in 2021.

14 Today

16 Current portfolio

The funds provide Pre-Seed to Series A+ investment finance for University connected companies. Cheque sizes range from £20k for the earliest pathfinder through to £500k for later stage propositions.

Always looking for cutting edge investable opportunities with high impact and high growth potential, we work across the breadth of University technologies, clustering our activities into four verticals: Life Science, Physical Science, Sustainability and Social Venturing.

Cambridge Enterprise Ventures also provides investment backing to the cohorts working with Founders at the University of Cambridge through their programmes.

In the year to 31st July 2025, the funds have completed over 30 transactions into 25 unique companies, each time placing investment cheques of between £20k and £500k to support the continued growth and development of the portfolio. Highlights from 2024/25 include first cheque investments into the Founders at the University of Cambridge START 2.0 cohort and follow-on investments into quantum networking company Nu Quantum and sustainable packaging company Xampla.

New companies by sector and financial year of first investment



As the availability of funds has increased over time as a result of realisations, we have been able to do more to support University connected businesses. This graph shows how we have expanded our activity, both by increasing the number of new companies we have been able to support each year and also the range of sectors in which we operate.

In 2024, the number of new companies supported increased significantly through initiation of Founders at the University of Cambridge. In 2025, there has been a greater focus on supporting existing portfolio businesses.

Total investments and realisations (‘000s)



Cash generative realisations are not predictable, occurring only when conditions are right for a particular business. Often we will see a gap of 3 or more years followed by a cluster of realisation activity. This mirrors the pattern seen in other later-stage funds. On average, it takes at least 8-10 years for an investment to generate a return.

Cumulative realisations (‘000s)



Value of assets under management (‘000s)



Each year our portfolio is valued and externally audited. The last audited figures available are to 31st July 2024 at which point the total assets under management were £75m.

20 Life Sciences portfolio

52North

AXIOM THERAPEUTICS

SPIREA

biotryp

Concr

T-Therapeutics

TransitionBio

HexagonFab

NoBACZ Healthcare

TRIMTECH THERAPEUTICS

PHARMENABLE
unlocking chemical space

Qkine

verinnogen

xterna

Established
2022

Life Sciences

Invested
£500k

Total raised
£48m

Image Credits: T-Therapeutics

Founders
Professor Allan Bradley, Dr Wei Wang, Dr Hanif Ali, Qunwei Wang, Haydn Prosser

T-Therapeutics

Built on the foundations of research from Professor Allan Bradley in the University's Department of Medicine, and previously at the Wellcome Sanger Institute, the T-Therapeutics OpTiMus® platform sidesteps shortfalls in immuno-oncology by creating a near-unlimited database of optimal T cell receptors (TCRs). These TCRs are then used as building blocks for new therapies to unlock the immune system's potential for cancer-specific solutions. The company has raised £48 million to support its first-in-class oncology and immunology programs.

Established
2022

Life Sciences

Invested
£430k

Total raised
£5.1m

Image Credits: 52 North Health

Founders
Dr Saif Ahmed, Umaima Ahmed

52North Health

52North develops cutting-edge medical devices to enhance patient care, particularly for those living with cancer. Their Neutrocheck® device is a low-cost finger-prick test and app which gives quick, reliable results at home, enabling cancer patients to assess their risk of neutropenic sepsis – a dangerous side effect of chemotherapy – without going to hospital. 52North's technology integrates seamlessly with digital platforms, enabling decentralised clinical decision-making and improving health equity.

Key facts

£21m
invested into 101 Life Sciences companies

£2bn
leveraged by the Life Sciences portfolio

£32m
returned from 34 exits

£18m
residual value in the portfolio at 31/07/2024

26 Physical Sciences portfolio


Am
ACCELERATED
MATERIALS


AETOSENSE


PARAGRAF
LEADING THE WAY
IN GRAPHENE ELECTRONICS


Pinepeak


aqdot


Cytora


POROTECH


river
Lane


illumion


Immaterial


Signaloid


sowish


JoltSynSor


nu
QUANTUM


trismik


ZOMP

Established
2016

Physical Sciences

Invested
£1.5m

Total raised
£94m

Image Credits: Riverlane

Founder
Dr Steve Brierley

Riverlane

Riverlane, the global leader in quantum error correction (QEC) technology, raised its $75 million in Series C round in 2024 helping the company to deliver its groundbreaking QEC roadmap Riverlane has built the world's largest dedicated quantum error correction team with close to a hundred interdisciplinary experts working on its core product Deltaflow ™. Applicable to quantum computers using all major qubit types, Deltaflow™ comprises proprietary QEC chips, hardware and software technologies working in unison to correct billions of errors per second, addressing growing global market demand for QEC technology.

Established
2012

Physical Sciences

Total raised
£94m

Realisation multiple
>8x

Founders
Richard Hartley, Dr Aeneas Wierner, Andrzej Czapiewski, Joshua Wallace

Cytora

Cytora is the risk digitisation platform for commercial insurance, giving insurers unparalleled control over how they digitise the risk intake they receive from trading partners to drive improved premium growth, profitability and service across all lines of business. The Cytora platform is LLM-powered and does not require training, enabling fast and scalable enterprise deployments. Cytora has raised over £29 million and is revenue-generating. The funds took a partial exit relatively early in the life of the business for an attractive multiple on our invested capital and still hold further shares today.

Key facts

£19.5m
invested into 77 companies

£1.1bn
leveraged in additional investments

£12m
returned from 28 exits

£26m
residual value in the portfolio at 31/07/2024

32 Sustainability portfolio

BARCAL

CAMBRIDGE ELECTRIC CEMENT

EVORALIS
Enzymes for a circular plastic economy

materials nexus

CGD
CAMBRIDGE GaN DEVICES

CPT
CAMBRIDGE PHOTON TECHNOLOGY

Molyon
Next generation batteries

nyobolt

CarbonRe

ColoriFix

Seprify

Sparxell

DeepForm

Echion Technologies

Xampla

xWATTS

Established
2017

Sustainability

Invested
£1.7m

Total raised
£50m

Founders
Dr Jean de la Verpilliere, Professor Michael De Volder, Professor Adam Boies, Dr Alexander Groombridge

Echion Technologies

Echion Technologies is a world leading developer of niobium-based, fast-charging battery materials. Following a successful Series B round in 2024, the company is executing on its strategy to see its innovative niobium-based anode material, XNO®, used in real-world applications. In November 2024, in partnership with CBMM, Echion opened the largest niobium-based anode production facility in the world, capable of producing the equivalent of 1GWh of lithium-ion cells each year. Earlier in 2024, Echion announced a partnership with Leclanché SA, a leading provider of energy storage solutions. The company continues to grow and scale from its base in Sawston, Cambridge.



Established
2016

Sustainability

Invested
£1m

Total raised
£40m

Image Credits: Colorifix

Founders
Professor Jim Ajioka, Dr Orr Yarkoni

Colorifix

Colorifix is harnessing the power of the natural world to colour textiles in a more sustainable way. The company has pioneered the first entirely biological process to produce, deposit and fix pigment onto textiles. Colorifix offers a radically different solution to conventional dyeing technologies that cuts the use of harsh chemicals and leads to huge reductions in water consumption across the dyeing process. The company raised an £18 million Series B round in 2022 to support this vision, led by H&M Group's corporate venturing arm. The company and its customers aim to make Colorifix's dyeing solution the standard for eco-friendly dyeing of the world's clothes in the coming years.

Key facts

2020
sustainability investing focus established

£10m
invested into 24 companies

£320m
leveraged in additional investments

£31m
residual value in the portfolio at 31/07/2024

38 The young & the future

40 Looking ahead

Today the University of Cambridge invests on average £5 million a year to support young companies with a strong University connection. We provide ongoing support through helping with business plan development; investor syndication and introductions; board expertise and we can (and frequently do) continue to invest at each round up to Series B. As an evergreen impact investor, our funds use ring-fenced University capital, with all returns supporting future Cambridge innovations.

In recent years we have started a small but growing portfolio of investable social venture businesses, which have a core social purpose associated with their mission and values. These companies are addressing areas as diverse as real-world conflict resolution to the provision of safe drinking water.

Could your new idea become a part of our portfolio?

We are always looking for investment opportunities from across the University of Cambridge research base whether from deeptech, life sciences, AI, software or social ventures.

Contact us today or participate in Founders at the University of Cambridge or the annual Postdoc Venture Creation Challenge to discover how we can support your first steps into entrepreneurship.

Social Ventures

aspuna · COSY SENSE · Kalamna · Majicom · OBLIQUITY · VOI. · WaterScope · WYA

Established
2024

Social Venture

Pathfinder
Investment

Founder
Dr Saussan Kahlil

Kalamna Global

Kalamna Global is an award-winning social enterprise that empowers families to connect with and celebrate their culture and heritage through the Arabic language. Arabic is a diglossic language, meaning there's a clear distinction between the spoken and written forms. Once a learner masters everyday conversational language, they can make the bridge to reading and writing formally in Standard Arabic. Kalamna Phonics™, an innovative phonics-based toolkit that draws on fundamental research conducted at the University of Cambridge, forms the basis of the Arabic language toolkit, which is now available through direct purchase and partnership with an international community of teachers and learners, establishing a new benchmark in evidence-based best practice in the teaching of modern Arabic.

Founders at the University of Cambridge

Cambridge Enterprise Ventures also provides direct investment support from the University to many of the young companies selected to participate in the programmes funded by Founders at the University of Cambridge. This is a strategic initiative of the University delivered by Cambridge Enterprise that seeks to equip founders with the skills for success through their multi-stage growth programs that leverage intensive mentoring, networks and access to a global community of experts, many of whom are also University of Cambridge alumni. The Founders at the University of Cambridge initiative programmes include:

SPARK: an annual 4-week residential incubator programme hosted with Kings E-Lab to accelerate validation that is targeted to students, researchers and recent alumni of the University.

SYNC: a part-time talent accelerator bringing the right people together at the right time to create groundbreaking AI and software startups.

START: a full-time pre-seed programme, accelerating a cohort of startups with a strong connection to the University, whose ideas and research have the potential to change the world.

AETOSENSE · biotryp · Cambridge Adaptive Testing · CAMBRIDGE VISION TECHNOLOGY · Gastrobody Therapeutics · NANOMATION · Pinepeak · Prodromic · Protonera · sowish · WILLIAM OAK DIAGNOSTICS · xterna

Established
2024

Founders
START 1.0, Sustainability

Total raised
£3.9m

Founders
SAFEs
Investment

Founders
Dr Ismail Sami, Professor Manish Chhowalla, Dr Zhuangnan Li, Dr Sai Giridhar Shivareddy

Molyon

Molyon's lithium–sulfur batteries deliver superior performance with twice the energy density of current lithium-ion batteries, while using more abundant materials such as sulfur. This development holds out the promise of unlocking the transformative potential of lithium-sulfur batteries at commercial scale. Molyon aims to decarbonise industries, supporting the transition to electrification and net zero.

Established
2025

Founders
START 2.0, Physical Sciences

Founders
Professor Nigel Collier, Rebekka Mikkola Marco Basaldella

Trismik

Trismik's technology is the world's first adaptive testing framework for large language models (LLMs), enabling real-time monitoring of AI models with first use cases including hallucinating customer chatbots. Inspired by psychometrics and redesigned for LLMs, the assessment dynamically explores the data, simulating human hackers to uncover areas missed by competitive techniques by evaluating toxicity, bias and accuracy. The Trismik platform dramatically reduces compute, delivering high-quality results and safer AI at 100x faster development cycles.

44 Governance

Investment decisions for the funds are taken either by the Ventures team within delegated authority limits, or by our Investment Committee. We are incredibly grateful to committee members for the time and diligent care they take in reviewing and supporting our activities.

The partnership that exists between our Investment Committee, the Ventures team, the University and portfolio companies is unique and truly represents Cambridge working at its best.

Investment Committee

John Lee

Chair of the Investment Committee

John was CFO of DisplayLink Corp, a market-leading USB graphics software and semiconductor business, from 2011-20, when it was acquired by Synaptics Inc. He has been actively involved in the Cambridge technology scene for over 35 years and has held senior management roles and/or been an investor in a number of startups, many of which have resulted in successful exits or IPOs.

Andy Sandham

Deputy Chair of the Investment Committee

Andrew has 35 years' experience in co-founding and building startup businesses in the biotechnology sector in the UK and USA. He has served in chairman, non-executive and executive roles with UK and US biotech startups throughout his career and has also served as a venture partner within Abingworth and Syncona.

Dr Barbara Domayne-Hayman	Biotechnology entrepreneur and Chief Business Officer, Autifony Therapeutics
Pam Garside	Fellow Cambridge Judge Business School & Chair, Cambridge Angels
Annalisa Gigante	Board Member, Henry Royce Institute
Dr Jim Glasheen	Chief Executive, Cambridge Enterprise
Dr Iris Good	MedTech entrepreneur
Dr Vishal Gulati	Venture Capital Investor, Founder and Managing Partner, Recode Ventures
John Halfpenny	Technology entrepreneur
Dr Andrew Herbert	Computer technology entrepreneur
Professor Patrick Maxwell	Regius Professor of Physic
Robert Miller	Chair in Aerothermal Technology and Whittle Lab Director
Heather Richards	Technology executive
Dr Paul Seabright	Deputy Director, Cambridge Enterprise
Professor Steve Young	Emeritus Professor of Information Engineering

Cambridge Enterprise Ventures team

Christine Martin	Head of Ventures
Dr Amanda Wooding	Deputy Head of Ventures
Chris Gibbs	Investment Director (Physical Sciences)
Christine Waterman	Ventures PA and Data Adminstrator
Gemma Siddall	Investment Associate (Sustainability)
Dr Jason Amartey	Investment Analyst
Julie Taylor	General Counsel (Ventures)
Mahesh Santiapillai	Investment Manager (Software & DeepTech)
Matt Doorbar	Legal Counsel
Megan Meredith-Rodriguez	Investment Associate (Deep Tech)
Piers Horlock	Investment Analyst
Dr Polly Machin	Senior Investment Associate
Vicky McDonnell	Ventures PA

In addition

Gerard Grech CBE	Managing Director, Founders at the University of Cambridge

We are also very grateful to the work of all those who have come before the current team some of whom are highlighted below, without whom this anniversary report would not be possible.

Anne Dobrée	previously Head of Seed Funds
Richard Jennings	previously Head of WILO and a driving force behind the funds
Bill Matthews	previously University Challenge Fund Manager
Dr Geraldine Rodgers	previously Head of Seed Funds
Joanna Womak	previously University Treasurer

Cambridge Enterprise
University of Cambridge
Hauser Forum
3 Charles Babbage Road
Cambridge, CB3 0GT, UK

cambridge-enterprise-ventures
enterprise.cam.ac.uk

CAMBRIDGE | Enterprise
Ventures